Current Therapeutic Research,
Journal Year:
2024,
Volume and Issue:
102, P. 100767 - 100767
Published: Dec. 3, 2024
Immunosuppressive
agents
like
cyclosporine
have
proven
effective
in
some
pediatric
cases,
although
there
are
limited
case
reports
considering
potential
risks
such
as
secondary
infections.
This
study
investigated
the
safety
and
efficacy
of
Cyclosporine
A
children
who
did
not
respond
to
high-dose
corticosteroids
combined
with
intravenous
immunoglobulin
(IVIG).
We
reported
four
patients
diagnosed
toxic
epidermal
necrolysis
(TEN)
received
treatment
at
our
institution.
All
were
previously
healthy
a
median
age
7
years,
comprising
three
boys
one
girl
(Table
1).
Epidermal
exfoliation
vesicular
lesions
ranged
from
32.5%
54.5%
body
surface
area
(BSA).
Despite
administration
(IVIG),
new
cutaneous
herpes
continually
emerged.
prompted
transition
(3-5
mg/kg/d)
administered
1-2
oral
doses.
Lesions
stopped
progressing,
bullous
started
epithelialization
after
13-27
days
hospitalization.
Cases
1
2
faced
bacterial
fungal
infections,
respectively,
their
temperatures
stabilized
antibiotics.
3
4
experienced
fever
again
when
dosage
was
tapered
off,
no
discernible
evidence
infection.
The
patients'
normalized
upon
continuation
therapy.
Among
patients,
presented
asymptomatic
elevated
serum
amylase,
which
met
diagnostic
criteria
for
acute
pancreatitis.
Two
showed
mildly
raised
aminotransferases,
experiencing
mild
coronary
artery
dilation,
two
contracted
onychomadesis,
developed
corneal
ulceration/keratitis
atretoblepharia,
eventually
resolved
vigorous
ophthalmologic
treatment.
None
had
any
permanent
sequelae
being
discharged
hospital
six
months.
is
generally
safe
fail
combination
IVIG.
Blood Cancer Journal,
Journal Year:
2025,
Volume and Issue:
15(1)
Published: April 3, 2025
Teclistamab,
a
BCMAxCD3-directed
bispecific
antibody,
has
shown
high
response
rates
and
durable
remissions
in
triple-class-exposed
patients
with
relapsed/refractory
multiple
myeloma.
We
performed
retrospective
study
evaluating
the
efficacy
safety
of
teclistamab
210
treated
at
9
academic
centers
from
five
countries
within
IMWG
Immunotherapy
Working
Group
Committee.
Patients
were
heavily
pretreated,
83%
having
triple-class
refractory
disease
44%
prior
BCMA-targeted
therapy.
With
median
follow-up
5.3
months,
overall
rate
(ORR)
was
67%
188
response-evaluable
patients,
including
55%
very
good
partial
or
better.
The
6-month
progression-free
survival
(PFS)
53%
(95%
CI,
46-61%)
73%
(67-80%),
respectively.
who
received
BCMA-directed
therapy
compared
to
BCMA-treatment-naïve
had
lower
ORR
(58.3
vs
74.0%;
P
=
0.03)
PFS
(6-month
43%
[95%
33-55%]
63%
[54-73%];
logrank
0.004).
Step-up
dosing
occurred
an
outpatient
setting
for
23%
patients.
CRS
54%
infections
reported
56.2%
22%
grade
≥3
infections.
In
this
multicenter
real-world
study,
we
found
that
can
lead
rapid
responses
pretreated
myeloma
comparable
profiles,
as
demonstrated
MajesTEC-1.
American Society of Clinical Oncology Educational Book,
Journal Year:
2024,
Volume and Issue:
44(3)
Published: June 1, 2024
This
article
endeavors
to
navigate
the
clinical
journey
of
bispecific
antibodies
(BsAbs),
from
elucidating
common
toxicities
and
management
strategies
examining
novel
agents
broadening
access
in
community
health
care.
These
drugs,
commonly
through
T-cell
activation,
result
shared
adverse
events
such
as
cytokine
release
syndrome
immune
effector
cell-associated
neurotoxicity
syndrome.
Variations
target
antigens
designs,
however,
might
introduce
unique
for
different
BsAbs,
warranting
specific
approaches.
Recent
US
Food
Drug
Administration
approvals
BsAbs
targeting
CD3
+
T
cells
linked
CD20
non-Hodgkin
lymphoma
B-cell
maturation
antigen
or
GPRC5D
multiple
myeloma
have
transformed
treatment
landscape
hematologic
malignancies.
Emerging
new
promise
further
enhancement
safety,
exploring
targets,
innovative
structures
trispecific
antibodies,
engagement
diverse
cells.
Simultaneously,
expansion
into
practices
is
underway,
demanding
a
multifaceted
strategy
that
encompasses
educational
initiatives,
operational
adaptations,
collaborative
frameworks.
ensures
comprehensive
access,
allowing
every
patient,
irrespective
geographical
socioeconomic
status,
benefit
these
advancements
cancer
therapy.
Blood Cancer Journal,
Journal Year:
2024,
Volume and Issue:
14(1)
Published: July 25, 2024
T
cell
engagers
(TCE)
such
as
chimeric
antigen
receptor
(CAR)
therapy
and
bispecific
antibodies
(BiAbs)
for
the
treatment
of
multiple
myeloma
(MM)
have
significantly
improved
clinical
outcomes,
but
also
raised
awareness
ensuing
post-treatment
secondary
immunodeficiency
hypogammaglobulinemia
(HG).
As
patients
with
MM
live
longer,
recurrent
infections
become
a
significant
component
therapy-associated
morbidity
mortality.
Treatment
HG
immunoglobulin
G
replacement
(IgG-RT)
has
been
mainstay
primary
(PI)
world,
extrapolation
to
recently
started
show
promising
outcomes.
However,
IgG-RT
initiation,
dosing,
route,
timing,
monitoring,
management
in
not
standardized
setting
TCE.
Progress
will
involve
greater
recognition
screening
underlying
immunodeficiency,
identification
risk-stratification
markers,
optimizing
management,
implementing
other
approaches
decrease
risk
infection.
In
this
review,
we
summarize
infection
risk,
HG,
strategies
relapsed
after
Frontiers in Oncology,
Journal Year:
2024,
Volume and Issue:
14
Published: April 10, 2024
Patients
with
relapsed/refractory
multiple
myeloma
(RRMM)
that
are
refractory
to
the
five
most
active
anti-MM
drugs,
so-called
penta-refractory
MM,
have
historically
had
dismal
outcomes
subsequent
therapies.
Progressive
immune
dysfunction,
particularly
of
T-cell
repertoire,
is
implicated
in
development
disease
progression
and
disease.
However,
advent
novel
immunotherapies
such
as
bispecific
antibodies
rapidly
changing
treatment
landscape
improving
survival
patients
RRMM.
Bispecific
engineered
simultaneously
engage
cytotoxic
effector
cells
(T
or
NK
cells)
malignant
plasma
via
binding
cell
antigens
extracellular
leading
activation
destruction.
Currently,
bind
CD3
on
T
epitopes
B-cell
maturation
antigen
(BCMA),
G-protein
coupled
receptor
family
C
group
5
member
D
(GPRC5d),
Fc
homologue
(FcRH5)
advanced
clinical
showing
unprecedented
response
rates
RRMM,
including
In
this
review
article,
we
explore
available
data
RRMM
summarize
efficacy,
safety,
toxicity,
outcomes,
mechanisms
resistance,
future
directions
these
therapies
JCO Oncology Practice,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 7, 2025
Multiple
myeloma
(MM),
the
second
most
common
hematologic
malignancy
in
United
States,
is
characterized
by
repeated
cycles
of
remission
and
relapse,
with
increasing
resistance
to
treatment
after
each
line
therapy.
Despite
virtually
incurable
nature
MM,
recent
therapeutic
breakthroughs
have
fundamentally
reshaped
its
landscape.
This
review
explores
evolving
care
paradigms,
spanning
from
newly
diagnosed
MM
relapsed
or
refractory
disease.
In
frontline
setting,
strategies
shifted
beyond
their
traditional
emphasis
on
autologous
stem-cell
transplant
eligibility
a
broader
categorization
patients
basis
suitability
for
quadruplet
relapsed/refractory
novel
immunotherapies,
including
chimeric
antigen
receptor
T-cell
(CAR-T)
therapies
bispecific
antibodies,
revolutionized
treatment,
offering
new
hope
previously
limited
options.
Precision
medicine
playing
growing
role
venetoclax
showing
significant
efficacy
t(11;14)
translocation,
advancing
targeted
therapy
this
subgroup.
On
horizon,
investigational
CAR-T
products
cereblon
E3
ligase
modulators,
such
as
mezigdomide
iberdomide,
may
provide
faster,
more
durable
responses
compared
current
therapies.
addition,
belantamab
mafodotin,
an
antibody-drug
conjugate
withdrawn
US
market
2022,
verge
reapproval
positive
results
randomized
trials.
While
these
offer
potential,
challenges
remain
managing
toxicity,
ensuring
accessibility,
optimizing
sequencing
strategies.
As
arsenal
expands,
need
personalized
plans
that
balance
quality
life
becomes
even
essential.
Pharmaceutics,
Journal Year:
2025,
Volume and Issue:
17(1), P. 135 - 135
Published: Jan. 19, 2025
Background/Objectives:
Multiple
Myeloma
(MM)
is
a
hematologic
malignancy
caused
by
clonally
expanded
plasma
cells
that
produce
monoclonal
immunoglobulin
(M-protein),
personalized
biomarker.
Recently,
we
developed
an
ultra-sensitive
mass
spectrometry
method
to
quantify
minimal
residual
disease
(MS-MRD)
targeting
unique
M-protein
peptides.
Therapeutic
antibodies
(t-Abs),
key
in
MM
treatment,
often
lead
deep
and
long-lasting
responses.
However,
t-Abs
can
significantly
decrease
the
total
polyclonal
(Ig)
levels
which
require
supplemental
IgG
infusion.
Here,
demonstrate
simultaneous
monitoring
of
M-proteins,
t-Abs,
Ig-titers
using
untargeted
assay,
offering
comprehensive
view
therapy
response.
Methods:
Sera
collected
between
2013
2024
from
four
patients
cerebrospinal
fluid
(CSF)
one
patient
who
received
various
were
analyzed
with
MS-MRD.
sequences
obtained
multi-enzyme
de
novo
protein
sequencing
approach.
Unique
peptides
for
M-proteins
selected
based
on
linearity,
sensitivity,
slope
coefficient
serial
dilutions.
Ig
constant
regions
monitored
isotype-specific
Results:
The
MS-MRD
multiplex
analysis
provided
detailed
information
drug
concentrations
response
kinetics.
For
example,
two
refractory
over
five
lines
therapy,
showed
deepest
responses
achieved
bispecific
t-Ab
(teclistamab)
treatment.
also
detectable
CSF
Conclusions:
This
proof-of-concept
study
shows
M-protein,
any
combination,
all
Ig-isotypes
within
run
feasible
provides
insight
into
